Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-amino-n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
2. Amisulpride
3. Barnetil
4. Dan 2163
5. Dan-2163
6. Lin 1418
7. Lin-1418
8. N-(ethyl-1-pyrrolidinyl- 2-methyl)methoxy-2-ethylsulfonyl-5-benzamide
9. Solian
10. Sultopride
1. 23694-17-9
2. Sultopride Hcl
3. N-((1-ethylpyrrolidin-2-yl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide Hydrochloride
4. Sultopridehcl
5. Lin-1418 Hydrochloride
6. Sultopride Hydrochloride [jan]
7. Barnotil
8. N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulphonyl)-2-methoxybenzamide Hydrochloride
9. 8q6926t32j
10. 55619-22-2
11. Dsstox_cid_28996
12. Dsstox_rid_83261
13. Dsstox_gsid_49070
14. Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy-, Hydrochloride (1:1)
15. Sultopride Hydrochloride (jan)
16. Cas-23694-17-9
17. Ncgc00185771-01
18. Unii-8q6926t32j
19. N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide Hydrochloride
20. Barnetil (tn)
21. Benzamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-, Hydrochloride (1:1)
22. N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide Hydrochloride
23. Einecs 245-829-0
24. Ncgc00184999-01
25. Sultopride Monohydrochloride
26. Schembl1417863
27. Chembl3182384
28. Dtxsid0049070
29. Ex-a3336
30. Tox21_113625
31. Tox21_113626
32. Hy-42849a
33. Sultopride Hydrochloride [mi]
34. Akos016010186
35. Ac-4565
36. Sultopride Hydrochloride [who-dd]
37. As-16926
38. Cs-0040603
39. Ft-0659859
40. D02208
41. 694s179
42. A816850
43. Sultopride Hydrochloride (lin-1418 Hydrochloride)
44. J-015185
45. Q27270888
46. N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulphonyl)-2-methoxybenzamide Monohydrochloride
47. N-(1-ethyl-2-pyrrolidinylmethyl)-2-methoxy-5-(ethylsulfonyl)benzamide Hydrochloride
48. N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide Monohydrochloride
49. N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxy-benzamide; Hydron; Chloride
50. N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide;hydrochloride
51. Benzamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-, Monohydrochloride
52. O-anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-, Monohydrochloride
| Molecular Weight | 390.9 g/mol |
|---|---|
| Molecular Formula | C17H27ClN2O4S |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 7 |
| Exact Mass | 390.1380062 g/mol |
| Monoisotopic Mass | 390.1380062 g/mol |
| Topological Polar Surface Area | 84.1 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 517 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Antidepressive Agents, Second-Generation
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
Dopamine Antagonists
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)
ABOUT THIS PAGE
A Sultopride HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sultopride HCl, including repackagers and relabelers. The FDA regulates Sultopride HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sultopride HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Sultopride HCl supplier is an individual or a company that provides Sultopride HCl active pharmaceutical ingredient (API) or Sultopride HCl finished formulations upon request. The Sultopride HCl suppliers may include Sultopride HCl API manufacturers, exporters, distributors and traders.
click here to find a list of Sultopride HCl suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Sultopride HCl Drug Master File in Japan (Sultopride HCl JDMF) empowers Sultopride HCl API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Sultopride HCl JDMF during the approval evaluation for pharmaceutical products. At the time of Sultopride HCl JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Sultopride HCl suppliers with JDMF on PharmaCompass.
Sultopride HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sultopride HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sultopride HCl GMP manufacturer or Sultopride HCl GMP API supplier for your needs.
A Sultopride HCl CoA (Certificate of Analysis) is a formal document that attests to Sultopride HCl's compliance with Sultopride HCl specifications and serves as a tool for batch-level quality control.
Sultopride HCl CoA mostly includes findings from lab analyses of a specific batch. For each Sultopride HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sultopride HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (Sultopride HCl EP), Sultopride HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sultopride HCl USP).
LOOKING FOR A SUPPLIER?
